Physician profile
Lawrence Perlmutter
NPI 1326102039
$12,147.86
in general payments reported to CMS, 2019-2025
41 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $1,120 · 2021: $1,354 · 2022: $1,606 · 2023: $1,484 · 2024: $2,883 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,711 · Education: $6.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,711.09 |
| Education | $6.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,241.23 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Astellas Pharma US INC | $1,483.96 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $1,024.50 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $1,018.53 | 2019-2021 | |
| Abbvie INC. | $627.21 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $619.88 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $533.32 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $514.02 | 2019-2021 | |
| Glaukos Corporation | $413.94 | 2024-2025 | Idose, Idosetr |
| Ocular Therapeutix, INC. | $384.10 | 2020-2025 | Dextenza |
| Allergan, INC. | $364.06 | 2019-2022 | |
| Dompe US, INC. | $320.30 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $295.29 | 2022-2024 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $256.31 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $251.50 | 2023-2025 | Vabysmo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $250.23 | 2020-2024 | Yutiq, Iluvien |
| Mallinckrodt Hospital Products INC. | $201.85 | 2022-2024 | Acthar |
| Biotissue Holdings INC. | $188.69 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $179.85 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $109.56 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $79.24 | 2019-2025 | Tecnis Simplicity |
| Amgen INC. | $68.44 | 2025 | Uplizna, Tepezza |
| Sight Sciences, INC. | $66.78 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $57.19 | 2020-2025 | Koselugo |
| Shire North American Group INC | $55.40 | 2019 | |
| Ani Pharmaceuticals, INC. | $53.05 | 2023-2025 | Iluvien, Purified Cortrophin Gel |
| Thea Pharma INC. | $51.47 | 2022-2023 | Iyuzeh |
| Biogen, INC. | $51.26 | 2022-2023 | |
| Harrow Eye, LLC | $42.12 | 2023-2024 | Vevye, Iheezo |
| Sandoz INC. | $41.47 | 2024 | Cimerli |
| Coherus Oncology, INC. | $40.83 | 2022-2023 | |
| Leadiant Biosciences, INC. | $39.48 | 2020-2022 | |
| Spark Therapeutics, INC. | $38.45 | 2022 | |
| Beaver-Visitec International, INC. | $35.18 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $29.57 | 2019 | |
| Recordati_rare_diseases_inc. | $23.53 | 2024 | Cystadrops |
| Horizon Therapeutics Plc | $22.76 | 2023 | Tepezza |
| Immunocore Limited | $22.36 | 2025 | Kimmtrak |
| Eyepoint US, INC. | $19.81 | 2019 | |
| Omeros Corporation | $16.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $14.74 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.